These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 3145745)

  • 1. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
    Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
    Mabuchi H; Kamon N; Fujita H; Michishita I; Takeda M; Kajinami K; Itoh H; Wakasugi T; Takeda R
    Metabolism; 1987 May; 36(5):475-9. PubMed ID: 3106756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H
    Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pravastatin in relation to low density lipoprotein receptor activity.
    Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S
    Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
    Yoshino G; Kazumi T; Iwai M; Iwatani I; Matsuba K; Kasama T; Matsushita M; Otsuki M; Baba S
    Atherosclerosis; 1988 Jun; 71(2-3):95-101. PubMed ID: 3135814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
    Marais AD; Naoumova RP; Firth JC; Penny C; Neuwirth CK; Thompson GR
    J Lipid Res; 1997 Oct; 38(10):2071-8. PubMed ID: 9374129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
    Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
    Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoadsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy.
    Jacob BG; Richter WO; Schwandt P
    Clin Investig; 1993 Nov; 71(11):908-12. PubMed ID: 8312683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.
    Nakaya N; Homma Y; Tamachi H; Shigematsu H; Hata Y; Goto Y
    JAMA; 1987 Jun; 257(22):3088-93. PubMed ID: 3108527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
    Saito Y; Goto Y; Nakaya N; Hata Y; Homma Y; Naito C; Hayashi H; Ito H; Yamamoto M; Takeuchi I
    Atherosclerosis; 1988 Aug; 72(2-3):205-11. PubMed ID: 3145746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
    Tobert JA
    Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia.
    Koizumi J; Koizumi I; Uno Y; Inazu A; Kajinami K; Haraki T; Yagi K; Kamon N; Miyamoto S; Takegoshi T
    Atherosclerosis; 1993 Apr; 100(1):65-74. PubMed ID: 8318064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.
    Saxenhofer H; Weidmann P; Riesen WF; Beretta-Piccoli C; Fragiacomo C; Wunderlin R; Noseda G
    Eur J Clin Pharmacol; 1990; 39(2):101-5. PubMed ID: 2123791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.
    Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Aukrust P; Retterstøl K; Ose L; Halvorsen B; Holven KB
    J Clin Lipidol; 2013; 7(2):109-16. PubMed ID: 23415429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects.
    Kobayashi J; Katsube S; Shimoda M; Furuhashi K; Kitano S; Masuda M; Maruyama T; Shinomiya M
    Clin Chim Acta; 2002 Jul; 321(1-2):107-12. PubMed ID: 12031599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.
    Mabuchi H; Haba T; Tatami R; Miyamoto S; Sakai Y; Wakasugi T; Watanabe A; Koizumi J; Takeda R
    N Engl J Med; 1981 Aug; 305(9):478-82. PubMed ID: 7254297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.